SBBC:CA:TSV-Simply Better Brands Corp (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 0.67

Change

+0.04 (+6.35)%

Market Cap

USD 0.06B

Volume

0.10M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Simply Better Brands Corp. operates as an omni-channel platform with diversified assets in the plant-based and wellness consumer product categories. The company focuses on plant-based, natural, and clean ingredient space. It focuses on consumer product categories, including CBD products, plant-based food and beverage, and pet care and skin care industries. The company offers Hemp derived products, including CBD under the Purekana, Seventh Sense, and Vibez brands; protein and nutritious bars under the Tru and TRUBAR brands through online in the U.S. and Canada, as well as through retailers; and skin care products under the No BS brand. The company was formerly known as PureK Holdings Corp. and changed its name to Simply Better Brands Corp. in May 2021. The company is headquartered in Vancouver, Canada. Simply Better Brands Corp. operates as a subsidiary of Heavenly Rx Ltd.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-15 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
RX:CA Biosyent Inc.

+0.05 (+0.45%)

USD 0.13B
LOVE:CA Cannara Biotech Inc

+0.01 (+1.67%)

USD 0.07B
ZYUS:CA ZYUS Life Sciences Corporation

N/A

USD 0.06B
LSL:CA LSL Pharma Group Inc.

+0.02 (+3.45%)

USD 0.05B
HASH:CA Simply Solventless Concentrate..

-0.01 (-1.75%)

USD 0.05B
DB:CA Decibel Cannabis Company Inc

-0.01 (-7.14%)

USD 0.03B
ROMJ:CA Rubicon Organics Inc

-0.02 (-3.80%)

USD 0.02B
PCLO:CA Pharmacielo Ltd

N/A

USD 0.02B
ELXR:CA Elixxer Ltd

N/A

USD 0.01B
VM:CA Voyageur Pharmaceuticals Ltd

-0.01 (-7.14%)

USD 9.76M

ETFs Containing SBBC:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 204.55% 89% A- 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 204.55% 89% A- 96% N/A
Trailing 12 Months  
Capital Gain 173.47% 94% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 173.47% 94% A 95% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -12.88% 37% F 30% F
Dividend Return -12.88% 37% F 30% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 68.79% 32% F 41% F
Risk Adjusted Return -18.72% 47% F 39% F
Market Capitalization 0.06B 85% B 86% B+

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.